Dr Christina Yap is a Reader in Biostatistics and Clinical Trials at Cancer Research UK Clinical Trials Unit (CRCTU), within the Institute of Cancer and Genomic Sciences at the University of Birmingham.
She is a chartered statistician with over 15 years’ experience in the design and analysis of clinical trials.
Within the CRCTU, Christina leads the early phase cancer trials portfolio (which comprises of more than 25 trials in solid tumours and haematological diseases), as well as late phase portfolios of Head and Neck cancer and skin cancer. She also has broad experience in other disease areas, both cancer and non-cancer, working collaboratively as a lead statistical methodologist in several trials.
Christina has a strong methodological interest in the development of efficient trial designs and analysis to support current and future research; motivated by a keen desire to ensure that trials are efficient and sufficiently robust to provide the results to influence clinical practice. To date, she has led the implementation of innovative, efficient designs in more than 10 trials (ranging from early phase I/II dose-finding to multi-arm multi-stage randomised Phase II/III designs, including basket, umbrella and platform designs and the application of Bayesian approaches to such settings), successfully translating novel designs into practice.
Christina is an internationally recognised expert in the design and implementation of efficient, adaptive designs in trials. She has been invited to speak at international conferences and symposiums, provide training courses to both statisticians and clinicians, and sits on international and national data monitoring committees. She is a funding panel member of CRUK Clinical Research Committee, MRC Confidence in Concept, and a co-opted member of CRUK Clinical Expert Research Panel; and an appointed member of two National Cancer Research Institute (NCRI) Clinical Studies Groups: Head and Neck Cancer and Skin Cancer. She is also part of the MRC Adaptive Designs Working Group and Stratified Medicine Working Group, NIHR Early Phase Group and an advisor for the West Midlands Research Design Service.